JP2024500064A5 - - Google Patents
Info
- Publication number
- JP2024500064A5 JP2024500064A5 JP2023534208A JP2023534208A JP2024500064A5 JP 2024500064 A5 JP2024500064 A5 JP 2024500064A5 JP 2023534208 A JP2023534208 A JP 2023534208A JP 2023534208 A JP2023534208 A JP 2023534208A JP 2024500064 A5 JP2024500064 A5 JP 2024500064A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibit
- activity
- ability
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121083P | 2020-12-03 | 2020-12-03 | |
| US63/121,083 | 2020-12-03 | ||
| US202163173090P | 2021-04-09 | 2021-04-09 | |
| US63/173,090 | 2021-04-09 | ||
| US202163215735P | 2021-06-28 | 2021-06-28 | |
| US63/215,735 | 2021-06-28 | ||
| US202163276066P | 2021-11-05 | 2021-11-05 | |
| US63/276,066 | 2021-11-05 | ||
| PCT/US2021/061834 WO2022120187A2 (en) | 2020-12-03 | 2021-12-03 | Method of determining resistance to checkpoint inhibitor therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500064A JP2024500064A (ja) | 2024-01-04 |
| JP2024500064A5 true JP2024500064A5 (https=) | 2024-12-11 |
Family
ID=81853603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534210A Pending JP2024500065A (ja) | 2020-12-03 | 2021-12-03 | Ｔｉｇｉｔベースのキメラタンパク質及びｌｉｇｈｔベースのキメラタンパク質を使用してがんを処置する方法 |
| JP2023534208A Pending JP2024500064A (ja) | 2020-12-03 | 2021-12-03 | チェックポイント阻害剤療法に対する耐性を決定する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534210A Pending JP2024500065A (ja) | 2020-12-03 | 2021-12-03 | Ｔｉｇｉｔベースのキメラタンパク質及びｌｉｇｈｔベースのキメラタンパク質を使用してがんを処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240011101A1 (https=) |
| EP (2) | EP4256344A4 (https=) |
| JP (2) | JP2024500065A (https=) |
| KR (1) | KR20230129229A (https=) |
| AU (2) | AU2021390545A1 (https=) |
| CA (2) | CA3201215A1 (https=) |
| IL (1) | IL303411A (https=) |
| WO (2) | WO2022120191A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4426725A2 (en) * | 2021-11-01 | 2024-09-11 | Shattuck Labs, Inc. | Chimeric proteins for treating cutaneous inflammation |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2024123890A1 (en) * | 2022-12-08 | 2024-06-13 | Shattuck Labs, Inc. | Methods of using light-based chimeric proteins |
| WO2025004683A1 (ja) * | 2023-06-30 | 2025-01-02 | 国立大学法人大阪大学 | がん検査方法及びがん治療剤 |
| WO2025042798A1 (en) * | 2023-08-18 | 2025-02-27 | Shattuck Labs, Inc. | Trim7 inhibitors and uses thereof |
| WO2025137678A1 (en) * | 2023-12-22 | 2025-06-26 | Roswell Park Cancer Institute Corporation | Targeting the pvr axis using car t cell therapy and combinations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| CA2608359A1 (en) * | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| CA3002587A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
| WO2017161188A1 (en) * | 2016-03-16 | 2017-09-21 | The Regents Of The University Of California | Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas |
| MX2019006072A (es) * | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| US20190367579A1 (en) * | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| US20200071380A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
| EP3930851A4 (en) * | 2019-02-28 | 2023-03-29 | Shattuck Labs, Inc. | COMBINATION THERAPIES |
| WO2025188614A1 (en) * | 2024-03-04 | 2025-09-12 | Shattuck Labs, Inc. | Peptide inhibitors of trim7 and uses thereof |
-
2021
- 2021-12-03 AU AU2021390545A patent/AU2021390545A1/en active Pending
- 2021-12-03 CA CA3201215A patent/CA3201215A1/en active Pending
- 2021-12-03 EP EP21901537.7A patent/EP4256344A4/en active Pending
- 2021-12-03 IL IL303411A patent/IL303411A/en unknown
- 2021-12-03 JP JP2023534210A patent/JP2024500065A/ja active Pending
- 2021-12-03 KR KR1020237022178A patent/KR20230129229A/ko active Pending
- 2021-12-03 CA CA3200920A patent/CA3200920A1/en active Pending
- 2021-12-03 US US18/265,046 patent/US20240011101A1/en active Pending
- 2021-12-03 EP EP21901540.1A patent/EP4255464A4/en not_active Withdrawn
- 2021-12-03 US US18/265,048 patent/US20240016892A1/en active Pending
- 2021-12-03 WO PCT/US2021/061841 patent/WO2022120191A1/en not_active Ceased
- 2021-12-03 JP JP2023534208A patent/JP2024500064A/ja active Pending
- 2021-12-03 WO PCT/US2021/061834 patent/WO2022120187A2/en not_active Ceased
- 2021-12-03 AU AU2021391820A patent/AU2021391820A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500064A5 (https=) | ||
| US10706954B2 (en) | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy | |
| JP2020022469A (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| US10441636B2 (en) | Method of diagnosis and treatment | |
| JP2018532992A (ja) | 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発 | |
| US10876115B2 (en) | Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| CN115992226A (zh) | 检测c1q表达水平的试剂在制备急性髓细胞白血病诊断或预后判断及治疗试剂中的应用 | |
| TW201823471A (zh) | 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法 | |
| US20200009177A1 (en) | Methods of inhibiting cancer stem cells with hmga1 inhibitors | |
| WO2024108114A2 (en) | Methods of selecting cancer patients amendable to treatment with immune checkpoint inhibitor | |
| CN117860772A (zh) | 用于评估胰腺癌患者化疗耐受性的生物标志物、试剂盒及药物组合物 | |
| Zou et al. | High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high‐level immune infiltration status | |
| KR102431271B1 (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| CA3065568C (en) | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy | |
| KR20250134312A (ko) | 암 관련 섬유아세포를 이용한 암 진단 또는 치료 방법 | |
| Ni et al. | TMT proteomics reveals that miR-425-5p promotes proliferation and metastasis of malignant melanoma by inhibiting SCARA5 | |
| WO2025245302A1 (en) | Methods, kits and systems for determining er activity of cancer and methods for treating cancer based on same | |
| US9283195B2 (en) | Methods used to characterize and treat glioblastoma | |
| HK40022696B (en) | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy | |
| HK40022696A (en) | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy | |
| Liu et al. | Screening of Immunosuppressive Factors for Identifying Breast Cancer Malignant Phenotypes Using mRNA Microarray Datasets | |
| HK1185945A (en) | Agtr1 as a marker for bevacizumab combination therapies |